Please visit answersincme.com/AFP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the most up-to-date recommendations and clinical evidence on oral calcitonin gene-related peptide (CGRP)–targeted therapies for the acute and preventive management of migraine disease. Upon completion of this activity, participants should be better able to: Review the latest American Headache Society consensus statement recommendations for the treatment of migraine disease; Describe the latest clinical evidence on approved oral CGRP-targeted therapies in the management of migraine disease; and Outline practical, patient-centered strategies to optimize the use of oral CGRP-targeted therapies in the management of migraine disease.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related